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                                                         BACKGROUND                                                                  
              Crescentic glomerulonephritis is the histologic manifestation of any severe glomerular injury 
resulting from immune/ inflammatory mechanisms.  It is characterized by the proliferation of resident 
glomerular and infiltrating inflammatory cells in the Bowmans space. Rapidly Progressive 
Glomerulonephritis (RPGN) is the clinical counterpart of Crescentic glomerulonephritis and is 
characterized by a rapid decline in renal function over days to weeks. The urine sediment is typically 
active in RPGN, showing dysmorphic erythrocyturia and erythrocytic cylindruria.   
            RPGN is a medical emergency because of the potential for relentless and rapid progression to end 
stage renal failure, if not treated. The crescents evolve through various stages and ultimately transform 
into fibrous elements resulting in permanent glomerular scarring. Therefore therapeutic interventions in 
Crescentic glomerulonephritis should precede such irreversible alterations in glomerular structure. Early 
identification and treatment of RPGN gain importance in this respect. 
           Crescentic glomerulonephritis is the culmination of severe glomerular injury and the etiology of 
Crescentic glomerulonephritis is heterogeneous. The clinical presentation and immuno pathologic 
characteristics of Crescentic glomerulonephritis are influenced by the etiology. Identification of the 
etiology is essential for instituting appropriate treatment. 
          The annual incidence of Crescentic glomerulonephritis is 0.7 to 1.0 per 1,00,000 population(8). 
Crescentic glomerulonephritis accounts for 9. 5% of glomerular diseases(4) and 5.1% of all biopsies 
done(5). Geographic variations exist with respect to the incidence and etiology of Crescentic 
glomerulonephritis.  
        The present study has attempted to identify Crescentic glomerulonephritis and study the etiology, 
clinico epidemiological features and outcome of the disease in our region. 
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                                                   AIM OF THE STUDY 
           This study aims to identify patients with Crescentic glomerulonephritis and study the 
etiology, clinical profile, prognostic factors and outcome of Crescentic glomerulonephritis.   
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                                                    REVIEW OF LITERATURE  
             Rapidly progressive glomerulonephritis (RPGN) is defined as a rapid loss of renal 
function occurring over days to weeks (usually a 50% decline in the glomerular filtration rate 
within 3 months) in association with nephritic urine sediment. The histologic counterpart of 
RPGN is crescentic glomerulonephritis. 
           Glomerular crescents can complicate any glomerulopathy, and represent the phenotypic 
expression of severe glomerular inflammation. 
Pathogenesis of crescentic glomerulonephritis: 
         Crescentic glomerulonephritis is the result of a final common pathway of glomerular injury 
that results in crescent formation. Multiple etiologies and pathogenic mechanisms can lead to the 
final common pathway, including many types of immune complex disease. The general dogma is 
that immune complex localization in glomerular capillary walls and mesangium, by either 
deposition or in situ formation or both, activates multiple inflammatory mediator systems. (46) 
This includes humoral mediator systems, such as the coagulation system, kinin system, and 
complement system, as well as phlogogenic cells, such as neutrophils, monocytes/macrophages, 
platelets, lymphocytes, endothelial cells, and mesangial cells. The activated cells also release 
soluble mediators, such as cytokines and chemokines. If the resultant inflammation is contained 
within the glomerular basement membrane, a proliferative or membranoproliferative phenotype 
of injury ensues with only endocapillary hypercellularity. However, if the inflammation breaks 
through capillary walls into Bowman space, extracapillary hypercellularity (crescent formation) 
results. Thus any severe glomerular injury producing breaks in the glomerular basement 
membrane can result in crescent formation. 
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        Complement activation has often been considered a major mediator of injury in immune 
complex glomerulonephritis; however, experimental data indicate the importance of Fc receptors 
in immune complex mediated injury. (47, 48) For example, mice deficient for the Fc gamma R1 and 
Fc gamma R3 receptors have a markedly reduced capacity to develop immune complex 
glomerulonephritis.   
Immunopathologic categorization of crescentic glomerulonephritis 
         Crescentic glomerulonephritis is categorized into three immunopathologic types based on 
the immunofluorescence characteristics.  
• Type  I  or  Anti  GBM  disease: Characterized by presence of linear deposits of 
immunoglobulin G along the glomerular basement membrane 
• Type  II    or  Immune  complex  glomerulonephritis: Characterized by the presence of  
granular deposits of immunoglobulin along the capillary wall or mesangium  
• Type III or Pauci immune nephritis: Characterized by the lack of immune deposits in the 
glomerulus. This type of glomerulonephritis is considered as a manifestation of small 
vessel vasculitis. When Pauci immune nephritis occurs as an isolated manifestation, the 
condition is termed “renal limited vasculitis”. Often the disease occurs as a renal 
manifestation of a more generalized systemic small vessel vasculitis. 
Etiology of crescentic glomerulonephritis:  
          Crescents occur when breaks in glomerular capillaries allow leakage of cells and plasma 
proteins into Bowman's space. Crescents can therefore occur in almost any disease leading to 
glomerular inflammation, and sometimes in renal diseases that do not primarily affect the 
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glomerulus. Widespread crescent formation, however, requires active and specific attack on 
glomerular capillaries, and is found in a more restricted set of diseases. The etiopathogenesis  of 
crescentic glomerulonephritis is summarized below 
Type I or Anti GBM nephritis Due to presence of circulating Anti GBM antibodies 
Type II or Immune complex nephritis Glomerular injury is mediated by in situ immune 
complex formation or by circulating immune 
complexes. Examples: 
1) Post infectious glomeruli nephritis 
2) IgA nephropathy 
3) Membrano proliferative glomerulonephritis 
4) Membranous nephropathy 
5) Lupus nephritis 
6) Henoch Schonlein nephritis 
7) Cryoglobulinemia  
Type III or Pauci immune nephritis Systemic or renal limited small vessel vasculitis 
 
Pathology  
Light Microscopy  
The light microscopic appearance of crescentic immune complex glomerulonephritis depends 
upon the underlying category of glomerulonephritis, for example, in their most aggressive 
expressions, membranoproliferative glomerulonephritis, membranous glomerulopathy, acute 
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postinfectious glomerulonephritis, or proliferative glomerulonephritis, including IgA 
nephropathy, can all have crescent formation. This underlying phenotype of immune complex 
glomerulonephritis is recognized best in the intact glomeruli or glomerular segments. There 
usually are varying combinations of capillary wall thickening and endocapillary hypercellularity 
in the intact glomeruli. This is in contrast to anti-GBM glomerulonephritis and ANCA-
glomerulonephritis, which tend to have surprisingly little alteration in intact glomeruli and 
segments in spite of the severe necrotizing injury in involved glomeruli and segments. In 
glomerular segments adjacent to crescents in immune complex glomerulonephritis, there usually 
is some degree of necrosis with karyorrhexis; however, the necrosis rarely is as extensive as that 
typically seen with anti-GBM or ANCA-glomerulonephritis. In addition, there is less destruction 
of Bowman capsule associated with crescents in immune complex glomerulonephritis, as well as 
less pronounced periglomerular tubulointerstitial inflammation. Crescents in immune complex 
glomerulonephritis have a higher proportion of epithelial cells to macrophages than crescents in 
anti-GBM or ANCA glomerulonephritis, which may be related to the less severe disruption of 
Bowman capsule and thus less opportunity for macrophages to migrate in from the interstitium 
Immunofluorescence Microscopy  
Immunofluorescence microscopy, as well as electron microscopy, provides the evidence that 
crescentic glomerulonephritis is immune complex mediated versus anti-GBM antibody mediated 
versus likely to be ANCA-associated. The pattern and composition of immunoglobulin and 
complement staining depends on the underlying category of immune complex 
glomerulonephritis that has induced crescent formation. For example, crescentic 
glomerulonephritis with predominantly mesangial IgA-dominant deposits is indicative of 
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crescentic IgA nephropathy, C3-dominant deposits with peripheral band-like configurations 
suggest crescentic membranoproliferative glomerulonephritis, coarsely granular capillary wall 
deposits raise the possibility of crescentic post-infectious glomerulonephritis, and finely granular 
IgG-dominant capillary wall deposits suggest crescentic membranous glomerulopathy. The latter 
may be a result of concurrent anti-GBM disease, which will also cause linear GBM staining 
beneath the granular staining, or concurrent ANCA disease, which can be documented 
serologically. About a quarter of all patients with crescentic immune complex glomerulonephritis 
are ANCA-positive, whereas less than 5% of patients with non-crescentic immune complex 
glomerulonephritis are ANCA-positive. This suggests that the presence of ACA in patients with 
immune complex glomerulonephritis may predispose to disease that is more aggressive. 
Electron Microscopy  
As with the immunofluorescence microscopy, the findings by electron microscopy in patients 
with crescentic immune complex glomerulonephritis are dependent upon the type of immune 
complex disease that has induced crescent formation. The hallmark ultrastructural finding is 
immune complex-type electron dense deposits. These can be mesangial, subendothelial, 
intramembranous, subepithelial, or any combinations of these. The pattern and distribution of 
deposits may indicate a particular phenotype of primary crescentic immune complex 
glomerulonephritis, such as postinfectious, membranous, or membranoproliferative type I or II. 
Ultrastructural findings also may suggest that the disease is secondary to some unrecognized 
systemic process. For example, endothelial tubuloreticular inclusions suggest lupus nephritis, 
and microtubular configurations in immune deposits suggest cryoglobulinemia. 
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As with all types of crescentic glomerulonephritis, breaks in glomerular basement membranes 
usually can be identified if looked for carefully, especially in glomerular segments adjacent to 
crescents. Dense fibrin tactoids occur in thrombosed capillaries, in sites of fibrinoid necrosis, and 
in the interstices between the cells in crescents. In general, the extent of fibrin tactoid formation 
in areas of fibrinoid necrosis is less conspicuous in crescentic immune complex 
glomerulonephritis than in crescentic anti-GBM or ANCA glomerulonephritis. 
Epidemiology: 
            The overall incidence of crescentic glomerulonephritis is between 2 and 5 per cent of 
unselected renal biopsies, regardless of the country of origin, be it France, England, America, 
India, or China ( Whitworth et al . 1976 ; Neild et al . 1983 ; Woo et al . 1986 ; Date et al . 1987 
; Heilman et al . 1987 ; Parag et al . 1988 ; Tang et al . 2001 ; Vendemia et al . 2001 ). Men are 
affected twice as commonly as women, and Afro-Caribbeans are relatively rarely affected, 
except by crescentic SLE. In one study from South Africa, idiopathic crescentic 
glomerulonephritis and anti-GBM disease were more common in White than Black patients (49).         
Clinical features: 
         Clearly, the precise clinical features of patients with crescentic glomerulonephritis vary 
with the underlying disease. Some features are relatively common to all causes of crescentic 
nephritis; hypertension is rare, loin pain not uncommon, constitutional symptoms found in 
approximately 50 per cent, urine almost always contains blood, red cell casts, granular casts, and 
protein, but nephrotic range proteinuria is rare. Rate of progression to renal failure is variable 
from hours (e.g. in anti-GBM disease) to months (some cases of MCGN).  
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   Non-specific markers of inflammation are usually raised, including C-reactive protein 
(CRP), peripheral blood leucocytes, alkaline phosphatase, immunoglobulins and platelets, and 
serum albumin is usually depressed. There may be a normochromic normocytic anaemia. 
Specific investigations include ANCA [detected both by immunofluorescence and enzyme-
linked immunosorbent assay (ELISA)] and anti-GBM antibodies, and markers for SLE [ANA, 
anti-double-stranded DNA (dsDNA) antibodies, serum complement]. These are the crucial 
investigations in all patients with RPGN. Imaging is usually non-specifically abnormal. 
Ultrasound will show swollen, echogenic kidneys with loss of the corticomedullary junction.  
Prognostic factors: 
              Objective assessment of the response to treatment of crescentic glomerulonephritis has 
been confounded by the heterogeneity of diseases included in most studies. It has become very 
clear over the last decade that the underlying immunopathological drive to crescent formation 
makes a substantial contribution to the outcome, but more importantly other biopsy features 
predict outcome much more than crescents themselves (26). As with other primary 
glomerulonephritides, the extent of tubulointerstitial scarring is a better marker of poor prognosis 
than a crescent score in almost all diseases causing crescentic glomerulonephritis. In anti-GBM 
disease, high crescent scores are associated with a worse outcome, but interstitial scarring better 
predicts lack of reversibility. In ANCA-associated vasculitis, the number of normal glomeruli 
and not the number of crescents is associated with renal recovery, and in IgA disease most 
studies have not demonstrated a worse outcome in patients with crescents in glomeruli. Renal 
function at presentation independent of histology is also a powerful predictor of outcome, and in 
clinical trials patients should be stratified by renal function as well as by precise diagnosis (27).  
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Treatment of crescentic glomerulonephritis: 
      In general, treatment is often divided into two phases in crescentic glomerulonephritis. 
First is induction of remission during the acute phase, followed by the next phase of maintenance 
therapy to control the underlying immunopathology in the longer term. The induction phase of 
treatment should both suppress the acute inflammatory features of crescentic glomerulonephritis 
and control the underlying aberrant immune response, while the maintenance phase should 
prevent scarring and prevent recrudescence of acute inflammation. Thus, in anti-GBM disease, 
plasma exchange removes circulating pathogenic autoantibodies, while prednisolone and 
Cyclophosphamide (and possibly other effects of plasma exchange) suppress the acute 
inflammatory response, cell infiltration, and further antibody synthesis. Prior to the use of any 
immunosuppressive therapies, the mortality from crescentic glomerulonephritis was                
100 percent (28).  Steroids improved the survival but only 25 per cent of patients escaped the need 
for dialysis. Patients with crescentic glomerulonephritis due to poststreptococcal 
glomerulonephritis had a better outcome. More recently, the prognosis for renal recovery has 
improved with the earlier diagnosis of crescentic glomerulonephritis, more precise disease 
characterization, and more carefully targeted treatments(29), although some studies fail to 
demonstrate any improvement in renal or patient survival over the last two decades(2) . The 
mainstay of therapy has remained relatively non-specific immunosuppression with combination 
therapies including steroids, Cyclophosphamide and Azathioprine, with or without 
methylprednisolone and plasma exchange.  
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Plasma exchange in crescentic nephritis  
       Plasma exchange has been used to treat almost all causes of crescentic glomerulonephritis, 
but with little controlled data in most instances. In anti-GBM disease, the rationale is clearly to 
remove pathogenic autoantibodies, but the process also has effects on inflammatory mediators 
and possibly cell-mediated immune function. Prior to the introduction of plasma exchange, 
almost all patients died and renal recovery was rare (30). The largest experience of plasma 
exchange was reported by Levy et al.,(31) in 71 patients treated intensively with plasma exchange, 
prednisolone and cyclophosphamide, with excellent renal and patient survival in patients 
presenting with mild or moderate renal failure. Patients presenting with dialysis-dependent renal 
failure rarely, but occasionally, recovered renal function. Other groups have used less intensive 
regimens, which may well affect the potential benefit of therapy.  
 The benefits of plasma exchange in anti-GBM disease subsequently led to the more 
widespread use of the treatment in other crescentic glomerulonephritides, especially in pauci-
immune vasculitis ( Rifle et al (32) ; Muller et al (33) ). The identification of the pathogenic role of 
ANCA antibodies has strengthened the rationale for plasma exchange in this setting. There have 
been a number of controlled trials reported since 1988, and the most cohesive study was reported 
by Pusey et al (34) in which only patients with non-anti-GBM pauci-immune crescentic nephritis 
were enrolled into a prospective, randomized trial. Plasma exchange was of significant benefit to 
patients presenting with severe renal failure requiring dialysis, but not to those with lesser 
degrees of renal impairment. The overall consensus from all these studies was that plasma 
exchange may offer benefit to patients with severe renal failure, but not to those with creatinine 
less than 500 μmol/l (35). This data prompted the multi-centre prospective randomized controlled 
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MEPEX trial, in which 151 patients with ANCA-associated crescentic glomerulonephritis and 
creatinine greater than 500μmol/l were randomized to plasma exchange or intravenous 
methylprednisolone as induction treatment in addition to conventional oral immunosuppression. 
The results clearly showed the benefit of plasma exchange in this group of patients with severe 
renal failure, with around 70 per cent coming off dialysis when treated with plasma exchange, 
but only 50 per cent recovering renal function when treated with methylprednisolone. Evidence 
for the benefit of plasma exchange in all other crescentic nephritides is poor (35). A controlled 
trial of plasma exchange (performed relatively infrequently) in SLE with moderate renal 
dysfunction has shown no benefit. One small series of patients with crescentic IgA disease has 
been reported in whom plasma exchange may have improved outcome (36).  
Methylprednisolone in crescentic nephritis  
          Intravenous methylprednisolone has been used extensively in all forms of crescentic 
nephritis (35, 37, 38). Only controlled comparison is the MEPEX study comparing plasma exchange 
with methylprednisolone in ANCA-associated crescentic glomerulonephritis with severe renal 
failure in which methylprednisolone was significantly worse at improving renal function. There 
have been no controlled comparisons of oral versus intravenous steroids, and there is a 
suggestion that intravenous steroids may be associated with an increased risk of osteoporosis, 
avascular necrosis and infection. Roccatello et al (39)  have reported 12 patients with crescentic 
IgA disease treated with intravenous methylprednisolone followed by oral immunosuppression, 
in whom the 5-year renal survival was significantly improved compared to an untreated group 
(91.6 per cent versus 37.5 per cent). This was not, however, a randomized prospective controlled 
study.  
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Other induction treatments  
          All treatment regimens for crescentic glomerulonephritis now include cyclophosphamide, 
since the demonstration of greater efficacy than azathioprine in patients with Wegener's 
granulomatosis(40) and microscopic polyangiitis,(41)  but there is continued debate as to the benefit 
of oral versus intravenous treatment. A number of trials have been performed with ambiguous 
results, and in general, it seems that toxicity and side-effects are less with an intravenous 
regimen, but that efficacy in controlling renal inflammation is also reduced. De Groot's meta-
analysis of the rather sparse data (143 patients enrolled into a number of studies) showed that 
pulse cyclophosphamide was significantly less likely to fail to induce remission (OR 0.29; 95% 
CI 0.12–0.73) and had a significantly lower risk of infection and leucopenia, but relapses 
occurred slightly (but not statistically significantly) more often. Intravenous immunoglobulin    
(at 2 g/kg over 3–5 days) has been used in a number of studies and appears to be beneficial in the 
short term, but with a risk of an acute deterioration in renal function(42). Treatment with 
chlorambucil, cyclosporin, mycophenolate, and anti-lymphocyte globulin has also been reported 
anecdotally in a few patents with crescentic glomerulonephritis. Anti-TNF therapy with either 
blocking antibodies (infliximab) or soluble receptors (eternacept) may be of benefit in ANCA-
associated diseases.  
Maintenance therapy  
The need for maintenance therapy in crescentic glomerulonephritis depends on the underlying 
disease. Long-term maintenance therapy is needed in almost all patients with ANCA-associated 
disease, since 50 per cent will relapse either with local or systemic disease, and long-term 
treatment can reduce relapses significantly(43). The CYCAZAREM trial clarified the optimum 
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therapeutic regimen by demonstrating that oral azathioprine after induction of remission was as 
effective as oral cyclophosphamide with a trend to less short-term toxicity, and undoubted 
longer-term benefits(44). Few, if any, patients with ANCA-associated crescentic 
glomerulonephritis should now remain on cyclophosphamide beyond 3 months. Patients 
relapsing on azathioprine may require further cyclophosphamide. Alternative agents include 
mycophenolate, anti-TNF therapy, cyclosporin, leflunomide, deoxyspergualin, and methotrexate 
(if renal function preserved). In contrast, anti-GBM disease is not a relapsing disease, and 
patients do not require long-term maintenance therapy. Patients can stop cyclophosphamide at 3 
months and be 'weaned' off steroids by approximately 6 months. There are no good data on the 
length of immunosuppression needed in patients with primary glomerulonephritis in crescentic 
phase, but where treatment has been initiated, it would be necessary to continue low-dose 
maintenance immunosuppression (prednisolone and azathioprine) for 1–2 years. In addition to 
ongoing immune-mediated damage, patients are also at risk of progressive renal decline from 
haemodynamic factors and progressive scarring, independent of the initial insult. This seems 
more likely in all crescentic glomerulonephritides if patients make only a partial recovery after 
induction treatment, and if their serum creatinine does not reduce to less than 250 μmol/l. 
Distinguishing relapse from progressive scarring can be very difficult, but is clearly an important 
distinction. Rebiopsy will help, and monitoring circulating ANCA may also be useful, although 
there are few studies to support the use of serial ANCA alone in guiding decisions about 
immunosuppression(45).  
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                                                  MATERIALS AND METHODS  
         Patients presenting to the Department of Nephrology, Madras Medical College with the 
clinical syndrome of Rapidly Progressive Glomerulonephritis (RPGN) from January 2008 to 
March 2010 were identified and subjected to physical examination, a range of non invasive 
investigations and renal biopsy to establish the presence of crescentic glomerulonephritis. Those 
individuals in whom the renal biopsy revealed crescentic glomerulonephritis were included in the 
study and analyzed for the etiology, clinical profile, prognostic factors and outcome. 
Inclusion criteria: 
1) Patients with crescentic glomerulonephritis in renal histopathology were included in the 
study. Crescentic glomerulonephritis was defined as involvement of atleast 50% of the 
total number of glomeruli in renal biopsy (in other words “diffuse” crescents).  
2) Both sexes and individuals more than 12 years of age were included. 
3) Individuals with preexisting co morbidities – hypertension, previous cerebro vascular 
accident, chronic liver disease to mention a few, were also included. 
4) Patients with pre existing glomerular diseases like IgA nephropathy, Henoch Schonlein 
Purpura and diffuse proliferative Lupus nephritis were included in the study if they 
presented with RPGN and renal biopsy revealed crescentic glomerulonephritis.  
5) Pregnant patients presenting with crescentic glomerulonephritis were also included.  
Exclusion criteria:  
1) Renal biopsy samples with focal crescent formation, defined as involvement of less than 
50% of the total number of glomeruli, were labeled as “glomerulonephritis with 
crescents” and were not included for further analysis. 
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2) Children who were 12 years or younger. 
Cinical evaluation:   
        Historic evaluation was focused on identifying the major renal manifestations of RPGN like 
oliguria, anuria, haematuria and edema, extra renal symptoms like arthralgia, skin rash, 
haemoptysis etc., and the duration of presenting symptoms. Precipitating events like respiratory 
infection, skin infection, drugs, smoking, and exposure to toxins or non adherence to prescribed 
medications in patients with preexisting diseases like Lupus nephritis were looked for.              
Co morbid diseases were identified. Thorough clinical examination, including general 
assessment, BP measurement, fundus examination, ENT examination and systemic examination 
was performed in all patients. 
Investigations:  
          Urine analysis, complete haemogram, coagulation profile, renal function tests and liver 
function tests were performed at entry and were repeated as necessary. Chest X-ray and 
ultrasonogram of KUB (Kidney, Ureter and Bladder) were routinely performed. CT scan of chest 
and paranasal sinuses were performed in selected patients (in suspected vasculitis and Anti GBM 
disease or in those with symptoms related to chest or sinuses). Investigations necessary for 
evaluation of co morbidities like MRI and CT scan of brain for evaluation of weakness of limbs, 
upper gastro intestinal endoscopy for decompensated liver disease etc., were carried out. 
Serologic testing for Hepatitis B and C viruses and Human Immuno deficiency virus were done 
in all patients. 
       Serologic work up for RPGN included assessment of serum complement profile (C3 and 
C4), ANA (Anti Nuclear Antibody) testing, ASO (Anti Streptolysin O) titer, P and C – ANCA 
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(Anti Neutrophil Cytoplasmic Antiboby) testing and Anti GBM antibody testing. In any patient 
serologic evaluation proceeded in a systematic manner as described in the review of literature. 
The method of ANA testing varied between patients. In some, it was performed by 
immunofluorescence while in others ELISA(Enzyme Linked Immuno Sorbent Assay) was 
employed. A titer of 1/100 or more in ELISA was taken as positive. Anti double stranded DNA 
was tested in those who were ANA positive. ANCA testing was done by immunofluorescence 
analysis of ethanol fixed neutrophils. ASO level more than 200 units/ml was considered 
significant. Anti GBM antibody testing was done by ELISA employing engineered glomerular 
basement membrane. 
        Renal biopsy was performed in all patients with RPGN after ultrasonographic localisation. 
Light microscopic analysis after staining with Haematoxylin and Eosin, Periodic Acid Schiff and 
Silver methanamine and immunofluorescence microscopy was done in all samples. Interpretation 
of results was done by a trained nephro pathologist.  
        Based on the immunofluorescence picture, Crescentic glomerulonephritis was categorized 
into three types, namely Anti GBM nephritis, Immune complex nephritis and Pauci immune 
nephritis as detailed in the review of literature.  
Establishing the etiology and therapeutic interventions:  
         The etiology of Crescentic glomerulonephritis was established by considering the 
immunofluorescence pattern in renal biopsy and the results of serologic investigations as 
summarized in the review of literature. Standard treatment protocols recommended in literature 
for each specific etiology of Crescentic glomerulonephritis (ex. Crescentic Lupus nephritis, 
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Crescentic IgA nephropathy, Anti GBM nephritis, Vasculitis etc.,) and reviewed in the previous 
section were adapted.  
Measures of outcome: (9) 
         Patients were followed up for a maximum of six months. The renal function, proteinuria 
and status of extra renal complications were periodically assessed during these six months of 
follow up. The findings at specified time points (one, three and six months) were recorded as 
follows. 
1) Status – alive or dead 
2) Extent of recovery of renal function – complete recovery (if renal function 
touched base line) partial recovery (patient became dialysis independent, but renal 
function had not touched baseline value) or no recovery ( patient dialysis 
dependent)  
3) Remission of proteinuria - complete remission( trace or less than trace 
proteinuria), partial    remission ( reduction in proteinuria by atleast 50% from the 
base line), no remission (not even partial remission achieved).  
           Outcome at three months was regarded as “favorable” if there was complete or partial 
recovery of renal function and as “adverse” if patient remained dialysis dependent or died.   
Assessment of prognostic factors:(9) 
          The following factors were analyzed for prognostic significance. 
 1) Age 
            2) Urine output at presentation 
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  3) Requirement for dialysis 
  4) Blood Pressure at presentation 
  5) Time duration between symptom onset & initiation of specific treatment 
  6) Histological parameters like extent of crescent formation, necrotizing lesions, chronic  
                    changes involving the glomeruli and tubulo interstitium 
  7) Etiology of crescentic glomerulonephritis 
         Patients were categorized in to two groups based on the outcome – “Responders” had 
favorable outcomes and “non responders” had adverse outcomes. The various clinical and 
histologic parameters were compared between the two groups for assessing their prognostic 
significance. 
Statistical analysis:  
        Comparisons of clinical and histologic data between subgroups were performed using 
Student's t-test for unpaired data, as well as the one-way ANOVA (Analysis of Variance). 
Relationships between parametrical parameters were determined using Pearson's correlation 
coefficient.   
        Statistical analysis was performed using a computer program package (SPSS 10.1 for 
Windows, Standard version, ©SPSS.Inc.), and a P value of < 0.05 was considered significant. 
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                                                          RESULTS 
                Patients presenting to the Nephrology department with the clinical syndrome of                  
RPGN (Rapidly Progressive Glomerulonephritis) from Jan 2008 to March 2010 were identified 
and investigated as per the protocol mentioned.  
               A total of 79 patients with RPGN were identified. Renal histopathology revealed 
diffuse crescentic glomerulonephritis in 26 patients. In the remaining 53 patients, renal biopsy 
revealed focal crescent formation in 41 patients and only diffuses endocapillary proliferation in 
12 patients. 
              The 26 patients with Crescentic Glomerulonephritis were included in the study and 
analyzed for the clinical presentation, etiology, outcome and prognostic factors. 
              The study population included 11 males & 15 females. The mean age of the population 
was   32.96 years and the age ranged from 14 years to 70 years. 
              In most patients crescentic glomerulonephritis occurred as a denovo manifestation i.e., 
in patients in whom there was no histological or clinical evidence of preexisting 
glomerulonephritis. A few patients had preexisting glomerulonephritis - five patients were 
known to have proliferative lupus nephritis and one patient had Henoch Schonlein purpura. 
             Several comorbid illness were noted in the study population which included DCLD  
(decompensated liver disease) with portal hypertension and esophageal varices in one patient, 
previous arterial hypertension and cerebrovascular accident with residual weakness in another, 
lymphedema of lowerlimbs due to filariasis in another and an incidentally detected  Hepatitis B 
21 
 
virus infection(non replicative infection without transaminitis) in one patient. In two patients 
crescentic glomerulonephritis manifested during the last trimester of pregnancy. 
            In eleven patients, fever preceded or occurred along with RPGN. Three of them also had 
diarrheal episodes. Two patients had symptoms of respiratory tract infection prior to the clinical 
presentation as RPGN. One patient had an unknown insect bite over lower limb, with a nodular 
eruption, one week prior to onset of symptoms. Three patients admitted taking drugs (for fever, 
diarrhea) prior to onset of edema & oliguria but the exact medications could not be identified. In 
one patient scabies antedated RPGN. In twelve patients no such apparent provoking events could 
be identified (Fig.1). 
             The major symptoms at presentation included edema, oliguria, anuria and haematuria 
occurring to variable degrees (Fig.2). While edema was a universal occurrence, urine output 
varied considerably among patients with crescentic glomerulonephritis. Nine patients had 
oliguria (defined as urine output <500 ml/24 hours), eight patients had anuria(defined as urine 
output < 100 ml/24 hours) and the remaining nine patients remained nonoliguric (Fig.3).  Visible 
haematuria occurred in seven patients.  
             Various extra renal manifestations found are depicted in Fig. 4. Arthralgia was the 
predominant extra renal manifestation, observed in eight patients, one of whom had preexisting 
Henoch Schonlein purpura and the remainder had preexisting diffuse proliferative lupus 
nephritis.  
             Three patients had skin rash.  Palpable purpura and erythema nodosum were the 
pertinent skin findings observed. One patient had fixed drug eruption. 
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             Haemoptysis was the presenting feature in a 15 years male and a CT scan of chest done 
later revealed diffuse air space consolidation bilaterally. Pleurisy accompanied RPGN in one 
patient. Three patients developed generalized seizures and weakness of limbs occurred in two 
patients. Weakness was accounted by spinal and frontal demyelination in MR imaging in one 
patient and the other had evidence of infarct in the territory of the MCA (Middle Cerebral 
Artery). One of the two pregnant patients developed antepartum haemorrhage at eighth month of 
gestation.      
              Hypertension (defined as a BP ≥ 140/90 mm Hg) was detected at presentation in twenty 
five patients. Four were initiated on antihypertensive medications in other centers before their 
referral to Nephrology department. One patient was normotensive (BP 120/80 mm Hg) at the 
time of presentation. 42.3% had BP ≥ 161/101 mm Hg and 38.5% had BP between 141/91 and 
160/100. The average BP of the population was 166.18/100 mm Hg. Hypertensive 
neuroretinopathy was recognized in six patients. Findings are summarized in BOX 1 and Fig.5.  
Box 1: BLOOD PRESSURE AT PRESENTATION IN CRESCENTIC GLOMERULONEPHRITIS 
Number of patients 
already instituted anti ‐
hypertensive drugs 
 
Number of patients 
(as % of  total) with BP 
< 140/90 mm Hg 
 
Number of patients(as % 
of  total) with BP 141/91 
to 160/100 mm Hg 
 
Number  of  patients 
(as %  of  total)     with 
BP ≥161/101 mm Hg 
  
 
04 (15.4%) 
                     
01 (3.8%) 
 
10 (38.5%) 
 
11 (42.3%) 
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         In all the twenty six patients with crescentic glomerulonephritis, immunofluorescence 
analysis of renal biopsy specimen was done which enabled categorization of crescentic 
glomerulonephritis into three types (Fig.6). Immune complex glomerulonephritis was found to 
be the most common cause of Crescentic Glomerulonephritis accounting for 69.2% of all cases. 
Pauci immune Crescentic Glomerulonephritis (vasculitis) contributed to 23.0% of all cases. Anti 
GBM nephritis was the least common variety accounting for 7.8% of crescentic 
glomerulonephritis. 
           Further identification of the etiology in immune complex glomerulonephritis was based 
on the immunofluorescence findings and serological investigations as detailed previously. A half 
of immune complex crescentic glomerulonephritis was due to lupus nephritis. Post Infectious 
Glomerulonephritis and IgA nephropathy each constituted 22.2% and membranous nephropathy 
5.6% of immune complex crescentic glomerulonephritis (Fig.7) 
            The clinical characteristics of each immunopathologic type of crescentic 
glomerulonephritis are summarized below. The urine out put at presentation in each type is 
shown in Fig.8. Both the patients with anti GBM nephritis presented with anuria, while the urine 
output varied considerably among patients with immune complex glomerulonephritis and pauci 
immune nephritis. 
           The average blood pressure at presentation in each category is shown in Box 2. 
Hypertension was found to be most pronounced in immune complex nephritis.                                                       
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Box 2: BP AT PRESENTATION IN CRESCENTIC GLOMERULONEPHRITIS 
Category of Crescentic Glomerulonephritis  Average BP in mm Hg 
Anti GBM nephritis  163.0/105.0 
Immune Complex nephritis  170.6/99.6 
Pauci immune nephritis  152.6/91.6 
 
           Extra renal manifestations varied according to the etiology of crescentic 
glomerulonephritis and are summarized in Box 3. Out of the two patients with Anti GBM 
nephritis one had evidence of pulmonary haemorrhage. The clinical presentation of crescentic 
lupus nephritis was characterized by coexpression of a plethora of extra renal manifestations like 
arthralgia, pleurisy, skin rash, oral ulcers and CNS manifestations. One of the two patients with 
Henoch-Schonlein nephritis manifested palpable purpura along with crescentic 
glomerulonephritis. Spinal and frontal demyelination occurred along with PIGN. No extra renal 
manifestations were observed in patients with vasculitis, implying that vasculitis was mainly 
renal limited in this series.   
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Box 3: PROFILE OF EXTRA RENAL MANIFESTATIONS IN CRESCENTIC GLOMERULONEPHRITIS 
Etiology  of Crescentic Glomerulonephritis Extra renal manifestations 
Anti GBM nephritis  Pulmonary haemorrhage 
Lupus nephritis  Arthralgia, Erythema Nodosum, oral ulcers, seizures 
CVA (Middle Cerebral Artery territory infarct), pleurisy 
Henoch Schonlein purpura  Palpable purpura,  arthralgia 
Vasculitis  None  
IgA nephropathy  Antepartum haemorrhage  
PIGN  Demyelination  of spine and frontal region 
 
         The average urinary protein excretion at presentation in each category of crescentic 
glomerulonephritis is shown in Fig.9. The highest mean spot urine protein creatinine ratio was 
seen in Anti GBM nephritis (6.30) followed by immune complex glomerulonephritis (5.92) and 
pauci immune nephritis (3.46) 
         The results of serologic investigations varied according to the etiology of crescentic 
glomerulonephritis. The findings in each category are summarized below (Box 4 through 8). 
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BOX 4: SEROLOGIC PROFILE OF ANTI GBM NEPHRITIS 
Total number of patients 2 
Number of patients positive for  Anti GBM antibody  2 
Serum complement( C3 & C4) Normal in all patients 
ANA Negative in all patients 
Number of patients tested for ANCA (p & c) 1 
Number of patients positive for  p ANCA 1 
Number of patients positive for  c ANCA 0 
 
BOX 5: SEROLOGIC PROFILE OF CRESCENTIC LUPUS NEPHRITIS 
Total number of patients  9 
Serum C3 Low in all patients 
Serum C4 Low in all patients 
ANA Positive in 5 patients, negative in 2 patients 
Anti ds DNA Positive in 5 patients, negative in 1 patient 
 
BOX 6: SEROLOGIC PROFILE OF CRESCENTIC POST INFECTIOUS GLOMERULONEPHRITIS 
Total number of patients 4 
Serum C3 Low in all patients 
Serum C4 Normal in all patients 
ASO  Positive in 1 patient, negative in 1 patient 
ANA Positive in 1 patient, negative in 2 patients 
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BOX 7: SEROLOGIC PROFILE OF CRESCENTIC IGA NEPHROPATHY & HENOCH SCHONLEIN NEPHRITIS 
Total number of patients  4 
Serum C3 & C4 Normal  
ANA Negative  
 
BOX 8: SEROLOGIC PROFILE OF VASCULITIS 
Total number of patients 6 
Serum C3 & C4 Normal in all patients 
P - ANCA Positive in 2 patients, negative in 4 patients 
C - ANCA Negative in all patients 
ANA Negative in all patients 
       
      Both patients with Anti GBM nephritis by histology demonstrated circulating Anti GBM 
antibodies. Out of the nine patients who had immunofluorescence feature and complement 
profile suggestive of lupus nephritis (both C3 and C4 low),  ANA(anti nuclear antibody) was 
tested in seven patients and found to be positive in five patients and negative in the remaining 
two(Fig.10). Anti double stranded DNA (Anti ds DNA) was tested in six patients and found to be 
positive in five patients.  
        ASO(anti streptolysin O) titer was determined in two out of four patients with PIGN and 
was found to be high in one patient. One patient with complement profile and histology 
suggestive of PIGN tested positive for ANA.  
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        ANCA (Anti neutrophil cytoplasmic antibody) testing was done in all six patients with 
pauci immune nephritis. P-ANCA was found to be positive in two out of six patients with pauci 
immune nephritis and negative in the remainder. C-ANCA was not detectable in any of these 
patients. Thus the majority of patients with vasculitis lacked any detectable circulating ANCA 
(Fig 11).  
         All patients with IgA Nephropathy by histopathology demonstrated normal serum 
complements and were negative for ANA.     
        Renal biopsy was performed in all 79 patients with RPGN. Three patients had transient 
visible haematuria following biopsy. No other complications related to renal biopsy was 
encountered. Only those patients with the histologic feature of circumferential crescent formation 
in atleast 50% of the glomeruli were included in the study. The extent of crescent formation in 
the study population ranged from 50% to 100%. On an average 77.46% of the glomeruli in the 
study samples revealed crescent formation. All ages of crescents were noted. Cellular crescents 
alone were seen in thirteen patients, fibrocellular crescents alone in six patients, fibrous crescents 
alone in two patients and a combination of cellular and fibrocellular crescents in five 
patients(Fig.12). Glomerular tuft necrosis was seen in three patients, two of whom had Anti 
GBM nephritis and the other patient had pauci immune nephritis (p–ANCA positive). The same 
patient with pauci immune nephritis showed intracapillary fibrin deposition along with 
glomerular tuft necrosis. Glomeruli or segments of glomeruli not involved in crescent formation 
were studied for endocapillary proliferation. Diffuse glomerular proliferation with or without 
exudation was seen in thirteen patients. Capillary wall thickening was evident in eight patients. 
To enable clinicopathologic correlation chronic tubulo interstitial changes were graded as none, 
mild, moderate and severe. Accordingly mild, moderate, severe and no chronic tubulo interstitial  
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changes were seen in twelve, four, two and eight patients respectively (Fig.13). Blood vessels 
appeared normal or thickened. Fibrinoid necrosis of an arteriole was observed in one patient who 
had pauci immune nephritis.  
        Average serum creatinine at presentation was 642µmol/L (range: 130 to 2413 µmol/L). 
Twenty three out of twenty six patients required dialysis during the course of follow up. All the 
twenty five patients with hypertension required oral antihypertensive drugs. Specific therapeutic 
measures included administration of immunosuppressive drugs like corticosteroids (IV pulse, 
oral), cyclophosphamide, Mycophenolate mofetil and institution of plasmapheresis. The decision 
to use a particular immunosuppressive regimen in each patient was based on the etiology of 
crescentic glomerulonephritis and the clinical and histologic characteristics as already addressed 
in the literature review. Twenty patients were managed with immunosuppressive measures. Two 
of them also required plasmapheresis (one patient with anti GBM nephritis and pulmonary 
haemorrhage and the other with vasculitis and severe renal failure). Six patients did not receive 
any form of immunosuppression. Late presentation with advanced sclerosing lesions in 
histopathology or comorbidities like liver disease, portal hypertension and esophageal varices 
and pyelonephritis precluded immunosuppression in these patients. Fig.14 depicts the extent of 
usage of immunosuppressive drugs and other strategies in the study population. The occurrence 
of crescentic glomerulonephritis in the third trimester of two pregnant patients warranted 
termination of pregnancy.  
       Adverse reactions related to immunosuppressive therapy included gastro intestinal side 
effects like nausea, vomiting and dyspepsia. One patient with Crescentic Lupus nephritis 
developed febrile neutropenia following fourth (monthly) pulse of Cyclophosphamide and 
expired because of sepsis. In others Cyclophosphamide appeared to be well tolerated without any  
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serious adverse effects like haemorrhagic cystitis or bone marrow suppression during the study 
period. 
       The mean delay between the occurrence of first renal symptom of crescentic 
glomerulonephritis and the institution of specific therapy was 17.45 days. This was accounted for 
by a mean delay of 13.76 days between onset of first renal symptom and presentation to clinic. 
       Patients were followed up at regular intervals upto a maximum of six months. A minimum 
of a month’s follow up was available for all patients. The mortality rate during the follow up 
period was 15.38%, i.e., four out of twenty six patients died, with two deaths occurring within 
three months of diagnosis and the remainder two occurring within six months. Death occurred 
due to noncompliance with dialysis and pulmonary edema in one patient, neutropenia and sepsis 
(secondary to immunosuppression) in one patient and psoas abscess and sepsis (not given 
immunosuppression) in another patient. One patient with anti GBM nephritis died of pulmonary 
haemorrhage.  
        At three months nineteen patients continued to follow up, five patients had defaulted and 
two expired. Out of these nineteen patients, seven patients remained dialysis dependent, nine 
patients became dialysis free and three patients never required dialysis (Fig.15).  In those who 
became dialysis free the average duration of dialysis dependency was 32.5 days. Renal function 
approached base line with serum creatinine falling less than 132 µmol/l (1.5 mg/dl) in four 
patients. The other five patients who became dialysis independent had a partial recovery of renal 
function with an average serum creatinine of 248 µmol/l.  Out of the five patients who had 
defaulted at three months, three remained dialysis dependent and two became dialysis 
independent by one month.   
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        At six months thirteen patients lost follow up, three patients died, four patients remained 
dialysis dependent, six patients were dialysis free. The status of patients at various time periods 
is shown in Fig.16. The outcome according to the immunopathologic categories is summarized 
in Box 9.                 
Box 9: OUTCOME AT 3 MONTHS ACCORDING TO IMMUNOPATHOLOGIC CATEGORIES 
Category    Anti GBM nephritis  
(n=2) 
Immune complex nephritis  
(n = 18) 
Pauci immune 
nephritis (n = 6) 
 ESRD  1 (50%)  6 (33.33%)  0 
Partial recovery of 
renal function 
0  4 (22.22%)  4 (66.66%) 
Serum creatinine < 1.5 
mg%( 132 µmol/L) 
0  4 (22.22%)  0 
Death  1 (50%)  1 (5.55%)  0 
Lost follow up  0  3 (16.66%)  2 (33.33%) 
Figures inside the box represent number of patients (as % of number of patients in each category) 
            
 The outcome at three months was considered “favorable” if there was partial or complete 
recovery of renal function and “adverse” if there was no recovery of renal function, i.e., patient 
developed ESRD (End Stage Renal Disease) or if the patient died. Accordingly those who had a 
favorable outcome were categorized as “Responders” and those whose outcome was adverse 
were categorized as “Non responders” (Box 10). 
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BOX 10: PATIENT CATEGORIZATION ACCORDING TO OUTCOME AT THREE MONTHS  
Category   Responders  Non responders 
Anti GBM nephritis (n = 2)  0  2 
Immune complex nephritis (n=18)  8  7 
Pauci immune nephritis (n=6)  4  0 
         
      The rate of complete and partial remission of proteinuria at three and six months for the three 
different immunopathologic categories of Crescentic Glomerulonephritis is shown in Box 11. 
  BOX 11: STATUS OF PROTEINURIA AT 3 MONTHS IN CRESCENTIC GLOMERULONEPHRITIS 
               Category                            3 months 
Partial remission  Complete remission 
Anti GBM nephritis (n = 2 )  0%  0% 
Immune complex nephritis (n = 18)  6 (33.33%)  0% 
Pauci immune nephritis (n = 6)  4 (66.66%) 0% 
          
           The clinical and histologic parameters were compared between two groups (responders 
and non responders) and are summarized in Box 12. Among the several factors that were 
assessed for prognostic significance, the average crescent score showed the maximum 
significance with a P value of 0.01. The percentage of glomeruli with fibrous or fibrocellular 
crescents also differed significantly between the two groups (P = 0.02). In responders only 
26.45% of the glomeruli revealed fibrous/fibrocellular crescents while in non responders 69.54% 
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of the sampled glomeruli demonstrated fibrous/fibrocellular crescents. The average diastolic BP 
between the two groups varied significantly. Other parameters like age, urinary protein 
excretion, mean latency to specific treatment, systolic BP and the requirement for dialysis failed 
to show a prognostic value. 
BOX: 12: ASSESSMENT OF PROGNOSTIC SIGNIFICANCE OF CLINICAL AND HISTOLOGICAL PARAMETERS  
 
 
 
 
Sl.no. Parameter Responders 
(n=12) 
Non responders  
(n=9) 
P value  
1 Mean age (years) 36.08 24.55 0.230 
2 Mean Systolic BP (mm. Hg) 157 171 0.190 
3 Mean Diastolic BP ( mm. Hg) 93 105 0.016 
4 Mean urine PCR 4.93 6.44 0.081 
5 Mean serum creatinine(µmol/L) 605.91 720.66 0.074 
6 Mean latency to specific treatment 17.9 days 21.4 days 0.610 
7 Average Crescent score 65.75% 92.77% 0.010 
8 % of glomeruli with fibrous or 
fibrocellular crescents 
26.45% 69.54% 0.020 
9 Requirement for dialysis 75% ( 9 out of 12) 100% ( 9 out of 9) 0.423 
10 Preexisting glomerular disease 2 4 0.090 
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                                                                     DISCUSSION 
           A total of seventy nine patients presenting with the syndrome of Rapidly Progressive 
Glomerulonephritis (RPGN) to the Nephrology department over a period of twenty seven months 
were identified and subjected to renal biopsy. Renal histology revealed that about 33% of 
patients (26 out of 79) with RPGN had diffuse crescentic glomerulonephritis, 52% (41 out of 79)   
had some form of glomerulonephritis (diffuse proliferative/ exudative   and proliferative/ 
mesangio proliferative) with only focal crescent formation and the remaining 15% (12 out of 79) 
had only diffuse endocapillary proliferation. 
         The various pathologic conditions which can present with the clinical syndrome of RPGN 
include diffuse crescentic glomerulonephritis, acute glomerulonephritis with focal crescent 
formation, diffuse endocapillary proliferation (when severe), acute interstitial nephritis and 
thrombotic microangiopathy(1). However thrombotic microangiopathy and acute interstitial 
nephritis were not encountered in the renal biopsy samples studied. 
        Only the twenty six patients with crescentic glomerulonephritis were included in the study 
and analyzed for clinical profile, etiology, outcome and prognostic factors. 
Demographic characteristics: 
        The study included included 11 males and 15 females. Children below 12 years of age were 
excluded from the study. The mean age of the study population was 32.96 years and the age 
ranged from 14 to 70 years. The mean age of patients in the three different immunopathologic 
categories of crescentic glomerulonephritis was as follows: 
 
35 
 
a) Anti GBM nephritis – 14.50 years 
b) Immune complex nephritis – 29.16 years 
c) Pauci immune nephritis – 50.50 years  
Even though Anti GBM nephritis can affect all ages and both sexes, there is a predilection for 
males in the second decade of life, females in the sixth and seventh decades of life (2). However 
the study detected one male and one female patient with Anti GBM nephritis, both in their 
second decades of life. Patients affected by pauci immune nephritis in this study tended to be 
older with a mean age of 50.50 years. The relative frequency of the three immunopathologic 
categories of Crescentic glomerulonephritis in different age groups is shown in Box 13. In 
individuals older than 60 years, pauci immune nephritis was found to be the commonest cause of 
Crescentic glomerulonephritis. Immune complex glomerulonephritis accounted for the majority 
of Crescentic glomerulonephritis in individuals younger than 60 years of age, with maximum 
occurrence between 20 and 60 years of age. Both cases of Anti GBM nephritis affected patients 
less than 20 years of age.  
 
Box  13:  RELATIVE  FREQUENCY  OF  IMMUNOPATHOLOGIC  CATEGORIES  OF  CRESCENTIC 
GLOMERULONEPHRITIS IN DIFFERENT AGE GROUPS:  
                   Category                                           Age in years 
12 – 20 ( n = 9) 20 – 60 (n = 13) > 60 ( n = 4) 
Anti GBM nephritis 22.2% ( 2 out of 9) 0% ( 0 out of 13) 0% ( 0 out of 13) 
Immune complex nephritis 66.6% ( 6 out of 9) 84.6% ( 11 out of 13) 25.0% ( 1 out of 4) 
Pauci immune nephritis 11.1% ( 1 out of 9) 15.4% ( 2 out of 13) 75.0% ( 3 out of 4)  
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Immunopathologic categorization: 
              Based on the immunofluorescence analysis of the renal biopsy specimen, three 
categories of crescentic glomerulonephritis were identified. Immune complex nephritis was the 
most common type observed  accounting for 69.2% (18 out of 26) of the cases followed by pauci 
immune nephritis occurring in 23% (6 out of 26). Anti GBM nephritis was seen in 7.8% ( 2 out 
of 26 ) of the population. This relatively high proportion of immune complex nephritis contrasts 
with the data from western nations where pauci immune nephritis accounts for   the   majority     
(>60%) of crescentic glomerulonephritis(3).  In a retrospective clinico pathologic study of 230 
patients with crescentic glomerulonephritis from South India by Anuradha Raman et al.,  
immune complex glomerulonephritis was found to be most common type accounting for 97.4%., 
followed by Pauci immune nephritis (2.17%) and Anti GBM nephritis (0.17%) (4). 
            A prospective study of 22 children with crescentic glomerulonephritis from Sanjay 
Gandhi Post Graduate Institute, Lucknow (5) also reported a similar preponderance of immune 
complex glomerulonephritis (86.36%) followed by anti GBM nephritis (0.09%) and pauci 
immune nephritis (0.04%). A similar scenario was reported by M.Vijayakumar et al., in South 
Indian children with crescentic glomerulonephritis (6). 
Etiologic profile of Crescentic Immune complex glomerulonephritis: 
           Among the various known etiologies of immune complex crescentic glomerulonephritis, 
lupus nephritis, Post Infectious Glomerulonephritis (PIGN), IgA nephropathy, Henoch Schonlein 
nephritis and Membranous nephropathy were identified in the study.  
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          Lupus nephritis was found to be the most common cause of immune complex 
glomerulonephritis accounting for 50% of patients (9 out of 18). PIGN, IgAN and Henoch 
Schonlein nephritis accounted for 22.2% (4 out of 18), 11.1% (2 out of 18) and 11.1% each 
respectively. Membranous nephropathy was diagnosed in one patient i.e., 5.6% of patients with 
immune complex nephritis. 
         A retrospective clinico pathologic study of Rapidly progressive Renal Failure (RPRF) in 
103 patients, conducted at the Department of Nephrology, Madras Medical college in the year 
2005 revealed that RPGN accounted for 98% of all cases of RPRF. Among the various causes of 
RPGN, Immune complex glomerulonephritis was the commonest cause of accounting for 93.2% 
of all cases of RPGN. Pauci immune nephritis and anti GBM nephritis each accounted for 2.9% 
and 1.9% of RPGN. Crescents were observed in 60.3% of the patients and Class 4 lupus 
nephritis was found to be most common cause of crescents (7).  
        However in several other clinico pathologic studies from India, PIGN was found to be the 
most common cause of crescentic immune complex nephritis (4, 5, 6).  Lupus nephritis was found 
to be the next common etiology in adult patients.  
        The exclusion of pediatric population (< 12 years age) from the present study might explain 
the preponderance of lupus nephritis. The other quoted studied had included children which 
might account for a higher proportion of PIGN. 
       Membranous nephropathy is a rare etiology of crescentic glomerulonephritis. Presence of 
crescents in membranous nephropathy should prompt search for anti GBM antibodies (14). Also 
secondary causes of glomerulonephritis like Lupus nephritis need to be excluded. The present 
study identified one patient with Crescentic membranous nephropathy in whom ANA (Anti 
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Nuclear Antibody) testing was done and found to be negative. ANCA and Anti GBM testing was 
precluded by logistic constraints. Hepatotrophic viral infections were also excluded. 
Crescentic transformation of preexisting glomerulonephritis:                      
            In most patients crescentic glomerulonephritis occurred as a denovo manifestation i.e., in 
patients in whom there was no histological or clinical evidence of preexisting 
glomerulonephritis. A few patients had preexisting glomerulonephritis - five patients were 
known to have diffuse proliferative lupus nephritis and one patient had Henoch Schonlein 
purpura. Out of the five patients with diffuse proliferative lupus nephritis, one patient refused 
immunosuppressive therapy and was remaining only on supportive measures, three patients had 
achieved partial remission of proteinuria after institution of Cyclophosphamide pulse therapy, 
and one patient had been initiated on Cyclophosphamide two months prior to Crescentic 
transformation. Two of these patients presented to the clinic with diarrhea as the initial 
manifestation. The occurrence of crescentic transformation in these patients exemplifies the 
inherent nature of the disease to flare, even while remaining on potent immunosuppressant like 
Cyclophosphamide. The patient with preexisting Henoch Schonlein purpura was an eighteen 
years old male who remained in remission before the occurrence of crescentic 
glomerulonephritis. Scabies antedated crescentic glomerulonephritis in this patient. 
Precipitating factors:  
       Among the known provoking factors for crescentic glomerulonephritis, skin infection was 
identified in two patients. One patient developed PIGN following insect bite and skin infection. 
The other patient had preexisting Henoch Schonlein nephritis and scabies preceded the crescentic 
transformation. It is estimated that infective episodes precede HSP in upto 50% of the cases (12). 
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There was no hydrocarbon exposure or smoking in both the patients with Anti GBM nephritis. 
No other toxin could be identified in the study. 
Renal and extra renal manifestations: 
          All patients with crescentic glomerulonephritis had edema, but the urine output varied 
considerably between patients. 30% of patients were anuric and 35% were oliguric while the 
remaining 35% were nonoliguric at presentation. A similar proportion of nonoliguric 
presentation was reported by Anuradha Raman et al.,(4). The urine output in crescentic 
glomerulonephritis depends on several factors like the speed at which crescents develop, the 
extent of crescent formation and the presence or absence of chronic tubulo interstitial changes. 
anti GBM nephritis, for instance is characterized by a fulminant presentation with oligo-anuria 
due to extensive crescent formation, with all the crescents occurring simultaneously. An 
insidious onset of crescent formation with synchronous involvement of the glomeruli or presence 
of chronic tubulo interstitial changes which could impair the urinary concentrating ability might 
account for non oliguric presentation(10). Both the patients with Anti GBM nephritis presented 
with anuria while the urine output varied in the other two immunopathologic categories. About 
27% of the study population had visible haematuria. The urine sediment revealed a nephritic 
picture in all patients. 
        Extra renal manifestations differed according to the etiology of crescentic 
glomerulonephritis. Pulmonary haemorrhage was seen in one patient with Anti GBM nephritis 
(Goodpasteur Syndrome). Extra renal manifestations were most pronounced in the immune 
complex nephritis group. About 61% of patients (11 out of 18) with immune complex nephritis 
had extra renal manifestations like pleurisy, arthralgia, skin rash, seizures, cerebral infarction and 
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spinal and frontal demyelination. Ante partum haemorrhage occurred in a patient with IgA 
nephropathy. Palpable purpura and arthralgia were observed in Henoch Schonlein purpura. 
Patients with lupus nephritis manifested oral ulcers, arthralgia, erythema nodosum, seizures and 
cerebral infarct.  
          Out of the six patients with pauci immune nephritis, only one patient had transient 
arthralgia. No other extra renal manifestations known to occur in systemic vasculitis (like 
respiratory tract granulomas, airway hyper reactivity, pulmonary haemorrhage, peripheral 
neuropathy, ocular manifestations, purpura or other deramatologic manifestations) were 
encountered in the study population. The renal biopsy revealed fibrinoid necrosis of medium 
sized blood vessel in yet another patient, indicating the systemic nature of the disease. Overall, 
about 66% (4 out of 6) of patients with pauci immune nephritis had a “renal limited” disease 
without any of the known systemic manifestations. 
          Renal-limited forms of pauci immune crescentic glomerulonephritis are thought to be 
related to small vessel vasculitis with exclusive involvement of the glomerular capillaries (11). 
This form of renal limited vasculitis was previously referred to as “Idiopathic Crescentic 
Glomerulonephritis”.  
Blood Pressure at presentation:  
          In general hypertension is less severe in crescentic glomerulonephritis (13). Involvement of 
the juxta glomerular apparatus in the inflammatory process with resultant impairment of renin 
production is postulated as the mechanism. . In the present study only one patient had a BP less 
than 140/90 mm Hg. The remaining 25 patients had hypertension to varying degrees. At the time 
of presentation, 38.5% of the study population had mild to moderate hypertension (defined as BP 
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141/91 to 160/100 mm Hg) and 42.3% of the population had severe hypertension (defined as  BP 
≥ 161/101 mm Hg). 
         Sodium and water retention accounts for hypertension in glomerular diseases. The PRA 
(Plasma Renin Activity) is suppressed by hypervolemia. Involvement of medium sized blood 
vessels in systemic vasculitis could result in renal ischemia and account for hypertension in 
Crescentic glomerulonephritis. The average time to presentation after the onset of symptoms was 
13.76 days. All patients had evidence of hypervolemia at presentation and the average serum 
creatinine at entry was 642µmol/L. Moreover 34.6% (9 out of 26) of the patients had pre existing 
hypertension. These factors could have contributed to severe hypertension that was seen in 
42.3% of the study population. 
        The average blood pressure at presentation, according to the immunopathologic categories 
was found to be highest in immune complex glomerulonephritis (170.6/99.6 mm Hg) followed 
by anti GBM nephritis (163.0/105.0 mm Hg) and pauci immune nephritis (152.6/91.6 mm Hg). 
        A few confounding factors with respect to interpretation of blood pressure, like pregnancy 
and liver disease were noted. These states tend to lower the BP themselves and even a marginally 
elevated BP may be considered equivalent to severe hypertension. These caveats need 
consideration in evaluating the prognostic significance of hypertension in crescentic 
glomerulonephritis. 
Urine protein excretion at presentation:  
       The highest mean urine protein excretion (urine PCR) at presentation, was recorded in anti 
GBM nephritis (6.30), followed by immune complex nephritis (5.92) and pauci immune 
nephritis (3.46). The difference in urine protein excretion between anti GBM nephritis and pauci 
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immune nephritis, immune complex nephritis and pauci immune nephritis each reached 
statistical significance implying that urine protein excretion was significantly higher in anti GBM 
nephritis and immune complex nephritis.  
      High grade proteinuria usually occurs in immune complex glomerulonephritis among the 
three immunopathologic categories. Proteinuria tends to be modest in anti GBM nephritis and 
Pauci immune nephritis. However highest proteinuria in this study was recorded in anti GBM 
nephritis. The small sample size (two patients) of anti GBM nephritis needs to be considered 
before drawing final conclusions in this regard.  
Serologic profile of Crescentic glomerulonephritis:  
        The serologic findings of crescentic glomerulonephritis are summarized in Box 4 through 
Box 8. Circulating anti GBM antibodies were detectable in both patients with anti GBM 
nephritis. One patient with histologic features of anti GBM nephritis also had circulating P – 
ANCA (double positive). Such double positive patients are reported in literature and may have a 
clinical course and response to treatment more typical of vasculitis than anti GBM disease. Anti 
GBM disease in such patients develop probably due to vasculitic glomerular damage and the 
ANCA detectable is P – ANCA (15).  
          Out of the nine patients who had immunofluorescence feature and complement profile 
suggestive of lupus nephritis (both C3 and C4 low),  ANA(anti nuclear antibody) was tested in 
seven patients and found to be positive in five patients and negative in the remaining two 
(Fig.10). Anti double stranded DNA (Anti ds DNA) was tested in six patients and found to be 
positive in five patients. ANA are present in about 90% of untreated lupus patients (16). Thus, 
nearly 10% of patients with active lupus could test negative for circulating ANA. In the present 
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study, about 28% (2 out of 7) of patients with crescentic lupus nephritis were found to be ANA 
negative. Anti ds DNA antibodies imply active renal disease, but lack sensitivity. About 83% (5 
out of 6) of patients with crescentic lupus nephritis tested positive for anti ds DNA antibodies. 
      Out of the four patients with PIGN (diagnosis based on immunopathology and complement 
profile) ASO titer was tested in two patients and found to be positive in one patient. A study 
found elevated ASO titers in only one-third of the patients, while anti-DNAse titres were high in 
73 per cent of postimpetigo cases(17). The streptozyme  test, which includes four antigens 
(DNAse B, Streptolysin O, hyaluronidase, and streptokinase), is elevated in nearly 80 per cent of 
the cases. The patient who tested negative also developed spinal and frontal demyelination from 
which she made a complete recovery in a month’s period. Demyelination in this patient could 
also be secondary to infection. Circulating ANA was detectable in one patient with PIGN. 
     ANCA (P and C) were tested in all six patients with Pauci immune nephritis. P – ANCA was 
detectable in two patients while none had C – ANCA. In the present study only two patients had 
systemic manifestations as previously mentioned. The remaining four patients had renal limited 
vasculitis. It is estimated that about 80% patients with renal limited vasculitis are P – ANCA 
positive (18).  However in the present study only 33.33% of patients were ANCA positive. Out of 
the two patients who were P –ANCA positive, one had renal limited vasculitis and the other had 
extra renal manifestation in the form of arthralgia. The patient with fibrinoid necrosis of medium 
sized blood vessel (and thus systemic small vessel vasculitis) did not have circulating ANCA. 
The clinical presentation and response to treatment of such ANCA negative systemic vasculitis 
closely resemble ANCA positive vasculitis (19).  
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Pregnancy and Crescentic glomerulonephritis: 
     Crescentic glomerulonephritis is a rare cause of renal failure in pregnancy (20). Reports of Anti 
GBM nephritis (21) and Pauci immune crescentic nephritis (22) during pregnancy are available in 
literature. Pregnancies invariably ended in fetal loss. The renal outcome on the other hand, varied 
from one patient to other. While renal function improved after termination of pregnancy and 
immunosuppressive therapy in some patients, others had a relentless progression to ESRD. 
     The present study identified two patients with crescentic glomerulonephritis occurring during 
pregnancy. One patient had PIGN, presented during second gestation at 8 months amenorrhea 
with RPGN and dialysis requiring renal failure. Pregnancy was terminated and IV followed by 
oral corticosteroid administered. Renal function recovered completely by one month. 
     The other patient was a primi who presented at 8 months amenorrhea with antepartum 
haemorrhage and dialysis requiring renal failure. Pregnancy was terminated and biopsy revealed 
Crescentic IgA nephropathy. Late presentation and severe chronic lesions in biopsy precluded 
immunosuppressive therapy. This patient landed up with ESRD and died of pulmonary edema by 
third month due to non compliance with dialysis. 
Short term outcome of Crescentic glomerulonephritis: 
     As previously summarized in Box 9 & 10 and Fig.15 & 16, at three months, out of the 26 
patientswith crescentic glomerulonephritis, 5 patients lost follow up, 2 patients were dead, 7 
patients remained dialysis dependent (ESRD) and the remaining 12 patients had complete or 
partial recovery of renal function and remained free of dialysis. Thus the outcome was “adverse” 
(death or ESRD) in 34.16% (9 out of 26) of patients with crescentic glomerulonephritis. 
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    46.15% (12 out of 26) of patients were dialysis independent at 3 months. The average serum 
creatinine at three months in this subgroup was 213.58µmol/L. In 4 of these patients, renal 
function approached baseline with creatinine falling less than 1.5 mg/dl (132µmol/L). At 3 
months the average urine PCR was 2.125 in those remained dialysis free. Partial remission of 
proteinuria was seen in 10 out of 12 patients (83.33%) while 2 patients failed to achieve any 
remission of proteinuria. None had a complete remission of proteinuria at 3 months. 
      The outcome differed according to the immunopathologic categories. Patients with Anti 
GBM nephritis had the worst short term outcomes, with 50% mortality and 50% developing 
ESRD. No mortality occurred in those with Pauci immune nephritis and all the 4 patients who 
were still following up at 3 months were dialysis independent. In other words no “adverse” 
outcome befell patients with Pauci immune nephritis. Patients with immune complex nephritis 
had both “favorable” and “adverse” outcomes. out of the 15 patients who followed up at third 
month, 33.33% developed ESRD, 5.55% died, 22.22% had complete recovery of renal function 
with creatinine falling less than 132 µmol/L and 22.22% had partial recovery of renal function 
(patient dialysis independent).   
    The Indian scenario of anti GBM nephritis was previously studied by M. Ahmad et al., form 
Sanjay Gandhi Post Graduate Institute, Lucknow (23). Out of the 18 patients studied nearly one 
third had pulmonary haemorrhage and 7 patients were considered eligible for 
immunosuppression and plasmapheresis. 4 patients recovered renal function after specific 
therapy. In the present study, both the patients had adverse short term outcome – one patient 
developed ESRD and the other died due to respiratory insufficiency from pulmonary 
haemorrhage. Presentation with advanced renal failure and pulmonary haemorrhage could have 
contributed to the dismal outcome in this subgroup. 
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       A retrospective study of anti GBM nephritis over 12 years period (1988 – 1999) was 
performed at the Department of Nephrology, Madras Medical College. 12 patients with anti 
GBM nephritis were identified and anti GBM nephritis was found to contribute to 10% of all 
Crescentic glomerulonephritis. A similar fulminant presentation with 25% of patients 
manifesting pulmonary haemorrhage was noted. The outcome was bleak with about 50% short 
term mortality.  
         The outcome of crescentic immune complex glomerulonephritis varied according to the 
etiology. Two patients with crescentic IgA nephropathy were identified in the present study. One 
patient was treated with pulse steroids and IV Cyclophosphamide and immunosuppression was 
deferred in the other considering the late presentation and advanced sclerosing lesions in 
histology. Both patients developed ESRD and one of them died due to non compliance with 
dialysis. PIGN was observed in 4 patients, one was lost to follow up, and one developed ESRD 
over short term, two patients recovered. Out of the 9 patients with crescentic lupus nephritis, 5 
patients (55.55%) recovered renal function and remained dialysis independent at 3 months of 
follow up, 3 patients (33.33%) developed ESRD and one was lost to follow up. One patient with 
crescentic membranous nephropathy progressed to ESRD. Two patients with crescentic Henoch 
Schonlein nephritis remained dialysis independent at 3 months. 
      In a large prospective study of 93 patients with lupus nephritis and crescents, with follow up 
lasting more than 50 months from China (24),  at third month follow up almost all patients were 
documented to have improvement in renal function and proteinuria. However only 62% of these 
patients presented with RPGN and only 15% required dialysis.all patients received induction 
with pulse steroids and IV Cyclophosphamide in this study.   
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      In the present study included only patients with diffuse crescentic glomerulonephritis and 
only one out of 9 patients with crescentic lupus nephritis did not require dialysis. These 
characteristics could account for the low remission rate of 55.55% at 3 months noted in the 
present study. 
      Among the 6 patients with pauci immune nephritis in the present study, there was no short 
term mortality and none required dialysis at 3 months. However two patients were lost to follow 
up at third month. One patient had recovered renal function by one month and became dialysis 
independent. The other patient remained dialysis dependent at one month and was lost to follow 
up at three months. 
      The outcome in pauci immune nephritis has improved after the use of Cyclophosphamide 
and plasmapheresis for induction. Remission rates following induction treatment vary from 35 – 
93% in Wegeners Granulomatosis and 75 – 89% in Microscopic polyangiitis (25). In the present 
study most patients (4 out of 6) had renal limited vasculitis and most (4 out of 6) were ANCA 
negative. The confinement of disease to renal microcirculation without any threatening 
manifestations like pulmonary haemorrhage was a favorable feature noted in the present study.  
Prognostic factors in Crescentic glomerulonephritis:  
      The short term outcome in crescentic glomerulonephritis depends on several clinical and 
histologic factors. Poor prognostic factors identified in the present study include  diastolic BP ≥ 
105 mm Hg, a crescent score ≥  92.77% and involvement of atleast 69.5% of the sampled 
glomeruli by fibrous or fibro cellular crescents.  
    Presence of severe tubular atrophy and interstitial fibrosis, glomerular tuft necrosis are other 
known predictors of poor outcome in crescentic glomerulonephritis (1). In the present study 
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chronic tubulo interstitial lesions were graded as mild, moderate, severe and none. Exact 
quantification in numerical terms, as percentage of interstitium involved was not done and this 
precluded statistical comparison between responders and non responders. In qualitative terms, 
about 42% of the responders had no chronic tubulo interstitial changes and the remaining 58% of 
patients had mild chronic tubulo interstitial changes. Among the non responders, 55.55% had 
mild, 33.33% had moderate and 11.11% had severe chronic tubulo interstitial changes. Thus 
moderate and severe chronic tubulo interstitial changes were noted among non responders. 
   Glomerular tuft necrosis was observed in two patients in the present study. One had anti GBM 
nephritis and pulmonary haemorrhage and the other Pauci immune nephritis. Both had advanced 
renal failure and required plasmapheresis. The one with Goodpasteur syndrome died and the 
other patient defaulted at one month when she was still dialysis dependent.   
    Other parameters like age, systolic BP, proteinuria and serum creatinine at presentation, the 
average time to institution of specific treatment and requirement for dialysis were tested as 
prognostic factors. But none of these factors could predict outcome and failed to qualify as 
prognostic markers in the present study. 
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                                                             CONCLUSION  
1) Crescentic glomerulonephritis was found to be equally distributed among both sexes in 
adults. 
2) In most patients, crescentic glomerulonephritis occurred as a denovo manifestation, while 
a few others had pre existing glomerulonephritis like lupus nephritis and Henoch 
Schonlein nephritis. 
3)  Fever, diarrhea, respiratory and skin infection preceded crescentic glomerulonephritis in 
majority (53%) of patients. 
4) Major symptoms at presentation included oliguria, anuria and haematuria. About 35% of 
the patients had a non oliguric presentation. 
5) Extra renal manifestations were pronounced in immune complex nephritis and anti GBM 
nephritis, while most of the patients (66%) with pauci immune nephritis had a renal 
limited disease. 
6) Hypertension was seen in all but one patient and about 42% of the patients had severe 
hypertension (BP ≥ 161/101 mm Hg). 
7) Immune complex nephritis was the predominant immunopathologic category of 
crescentic glomerulonephritis accounting for about 69% of all cases, followed by pauci 
immune nephritis (23% of cases) and Anti GBM nephritis (8% of cases). 
8) A half of immune complex glomerulonephritis was due to Lupus nephritis. PIGN 
accounted for 22%, IgA nephropathy and Henoch Schonlein purpura for 22% and 
membranous nephropathy accounted for 6% of immune complex nephritis. 
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9) Urine protein excretion was highest in Anti GBM nephritis and lowest in Pauci immune 
nephritis. Mean urine protein excretion was in the nephrotic range in both Anti GBM 
nephritis and Immune complex nephritis. 
10) Most patients with pauci immune nephritis were ANCA negative. Only P – ANCA was 
detectable in the study population. One patient was “double positive” and had both 
circulating Anti GBM antibody and P – ANCA. 
11) On an average 77.46% of the glomeruli revealed crescents. All ages of crescents were 
seen. Glomerular tuft necrosis was seen in 11.5% of the patients. 
12) About 88% of patients required dialysis. Mean serum creatinine at presentation was 
642μmol/L. 
13) IV and oral steroids, Cyclophosphamide and plasmapheresis were employed as treatment 
modalities. 
14) Mean latency between symptom onset and specific treatment was 17.45 days. 
15) At three months about 7.6% died, 27% remained dialysis dependent (ESRD), 46% had 
partial or complete recovery of renal function and remained dialysis free and 19.5% were 
lost to follow up. 
16) Outcome was worst in Anti GBM nephritis with 50% mortality and 50% ESRD. 
17) Pauci immune nephritis had the best outcome with none dying or remaining dialysis 
dependent. 
18) Outcome was mixed in immune complex nephritis with 33% mortality, 44% recovering 
renal function and about 5% developing ESRD.  
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19) Poor prognostic factors identified in the present  study  include   diastolic  BP  ≥ 105 mm 
Hg, a crescent score ≥  92.77% and involvement of atleast 69.5% of the sampled 
glomeruli by fibrous or fibro cellular crescents.  
 
 
 
    
       
    
    
 
 
 
 
         
 
CRESCENTIC GLOMERULONEPHRITIS 
F = Fibrous;  FC = FibroCellular; C= Cellular;  * = not discernable; TA = Tubular Atrophy;  IF = Interstitial Fibrosis; Gr = GranularL=Linear; 
M=Mesangial;  P=peripheral ; Mes.Prolif = Mesangial Proliferation; IgAN = IgA Nephropathy; Exud.Prolif=Exudative proliferation;                         
mod = moderate; 
 
Sl. 
no 
Name  Crescent   Tuft 
necrosis 
Capillary 
walls 
Endocapillary
proliferation  
TA/IF  Interstitial 
inflammation 
Blood vessels  Immunofluorescence 
%  Age  
1  Vignesh   50  C   none  *  DPGN  none  mild  normal  Gr, P, M, fullhouse 
2  Narayanan   100  FC  none  *  *  mild  mild  normal  No significant deposits 
3  Suresh   66  C   none  normal  Mes. Prolif.  mild  none  Thickened  M , IgA  
4  Mumtaj   80  C   none  Thick   DPGN  none  Diffuse  normal  Gr, P, M, fullhouse 
5  Sambasivam   100  C   none  *  Exud .Prolif  none  mild  normal  Gr, M, P, IgG 
6  Munusamy   70  FC  none  *  *  mild  Dense patchy  normal  No significant deposits 
7  Rajammal   90  C   none  *  Exud .Prolif  none  none  normal  Gr, M, P, IgG,IgM,C3 
8  Periyandavar   50  C   none  *  Exudation   none  Dense patchy  Fibrinoid necrosis  No significant deposits   
9  Elumalai   100  FC,C  none  Thick  *  mild  Diffuse   Thickened  Gr, M, P, IgG,IgM 
10  Ramanibai   50  C  none  normal  Mes. Prolif.  none  mild  Thickened  M , IgA 
11  Dharman   80  FC,C  none  Thick/spikes  none  mod  dense  normal  Gr, P, IgG, IgM 
12  Karthik   100  FC  Present  *  *  mod  mild  normal  L, IgG 
13  Shanthi   90  C   none  *  DPGN  mild  Dense patchy  Thickened   Gr, P, M, fullhouse 
14  Balakrishnan   80  C  none  *  *  mild  mild  normal   No significant deposits 
15  Jayamani   68  C  none  normal  Mes. Prolif  mild  mild  Thickened   No significant deposits  
16  Feroz khan   100  FC  none  *  DPGN  mild  Dense   Thickened   Gr, P, M, fullhouse 
17  Valliammal   80  C,FC  Present   Fibrin seen *  none  Diffuse  normal  No significant deposits 
18  Nirmala   60  C   none   *  Exud .Prolif  none  diffuse  normal  Gr, P, M IgM, C3 
19  Ezhilarasi   60  C,FC  None   Reduplicated Exud .Prolif  mild  mild  Thickened  Gr, P, M, fullhouse 
20  Shaheen   50  C   none  Thick  DPGN  mild  mild  Thickened  Gr, P, M, fullhouse 
21  Nooriya zarith   75  FC  none  *  Mes. Prolif  severe  Dense patchy  Thickened   M , IgA 
22  Umesh   70  C,FC  none  *  Mes. Prolif  mod  mild  Thickened   M , IgA 
23  Jayanthi   100  FC  none  Thick  DPGN  mod  mild  Thickened  Gr, P, M, fullhouse 
24  Kavitha   100  F  Present   *  *  mild  mild  normal   L, IgG 
25  Soundarya   55  C  none  Thick  DPGN  mild  Dense patchy  Thickened  Gr, P, M, fullhouse 
26  Kalaimathy   90  F  none  Thick   DPGN  severe  mild  Thickened  Gr, P, M, fullhouse 
CRESCENTIC GLOMERULONEPHRITIS 
n =normal;   neg = negative;     ‐‐‐  =  not done;   Lt =left;  ↓= low;  pos =positive; Demyelin. = demyelination C4 & right frontal region in MRI  
Sl.
no 
Name   Urine  
PCR 
Urine 
sediment 
HB 
gm
% 
TC  Platelets
Lakh/μl 
Entry 
Creat. 
μmol/l 
Chest/         
sinus/ 
other 
imaging 
C3  C4 ANA  Anti 
ds 
DNA 
Anti 
GBM 
ASO 
 
ANCA 
 
HIV       
HCV 
HBV p  c 
1  Vignesh   4.70  Nephritic  9.0  7400  1.9  350  n  ↓  ↓  pos  pos  ‐‐‐  ‐‐‐  neg  neg  neg 
2  Narayanan   3.60  Nephritic  6.5  5900  2.4  2413  n  n  n  neg  ‐‐‐  ‐‐‐  ‐‐‐  neg  neg  neg 
3  Suresh  8.63  Nephritic  10.6  6200  2.5  335  n  n  n  ‐‐‐  ‐‐‐  ‐‐‐  neg  ‐‐‐  ‐‐‐  neg 
4  Mumtaj   4.74  Nephritic  7.8  4200  1.4  215  n  ↓  ↓  neg  neg  ‐‐‐  neg  ‐‐‐  ‐‐‐  neg 
5  Sambasivam   5.80  Nephritic   10.2  9100  2.6  512  n  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  neg 
6  Munusamy   2.22  Nephritic  7.8  11200  1.8  627  Lt lacunar  
infarct
n  n  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  neg  neg  neg 
7  Rajammal   5.82  Nephritic   10.2  5200  2.8  510  Demyelin.   ↓  n  neg  ‐‐‐  ‐‐‐  neg  ‐‐‐  ‐‐‐  neg 
8  Periyandavar   4.06  Nephritic   13.8  6700  3.0  673  n  n  n  neg  ‐‐‐  ‐‐‐  ‐‐‐  neg  neg  neg 
9  Elumalai   8.80  Nephritic   7.2  12800  3.0  2154  n  ↓  n  neg  ‐‐‐  ‐‐‐  ‐‐‐  neg  neg  neg 
10  Ramanibai   4.80  Nephritic  8.0  18800  3.5  693  cardiomegaly  n  n  neg  ‐‐‐  ‐‐‐  ‐‐‐  neg  neg  neg 
11  Dharman   5.20  Nephritic   10.5  8700  4.2  509  n  n  n  neg  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  neg 
12  Karthik  8.80  Nephritic   8.5  10800  2.6  745  B/L lung 
opacities 
n  n  neg  ‐‐‐  pos  ‐‐‐  pos  neg  neg 
13  Shanthi  5.40  Nephritic   5.2  4600  2.0  130  n  ↓  ↓  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  neg 
14  Balakrishnan   4.50  No RBCs  11.0  7000  2.2  590  n  n  n  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  neg  neg  neg 
15  Jayamani   3.60  Nephritic   9.2  7400  2.6  281  n  n  n  neg  ‐‐‐  ‐‐‐  neg  pos  neg  neg 
16  Feroz khan   4.8  Nephritic  5.5  4300  1.2  344  n  ↓  ↓  pos  pos  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  neg 
17  Valliammal   2.80  Nephritic   6.8  6700  2.2  1320  n  n  n  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  pos  neg  neg 
18  Nirmala   4.30  Nephritic  5.6  11200  2.0  400  n  ↓  n  pos  ‐‐‐  ‐‐‐  pos  ‐‐‐  ‐‐‐  neg 
19  Ezhilarasi   4.70  Nephritic  5.8  11800  1.8  446  n  ↓  ↓  neg  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  HBSAg +,e‐ ve 
20  Shaheen   3.86  No RBCS  8.0  7600  2.0  287  Pericard. Eff.   ↓  ↓  pos  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  neg 
21  Nooriya zarith  5.76  Nephritic  7.8  6800  3.6  498  n  ‐‐‐  ‐‐‐  neg  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  neg 
22  Umesh   6.20  Nephritic  7.9  10400  2.3  452  n  n  n  neg  ‐‐‐  ‐‐‐  neg  ‐‐‐  ‐‐‐  neg 
23  Jayanthi   6.80  Nephritic   6.8  4700  2.1  654  n  ↓  ↓  pos  pos  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  neg 
24  Kavitha   3.80  Nephritic  7.4  5400  2.9  784  n  n  n  neg  ‐‐‐  pos  ‐‐‐  neg  neg  neg 
25  Soundarya   8.50  Nephritic  9.2  13800  1.0  435  Lt MCA infarct  ↓  ↓  pos  pos  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  neg 
26  Kalaimathy   7.80  Nephritic  8.4  6400  2.6  346  Psoas absces  ↓  ↓  pos  pos  ‐‐‐  ‐‐‐  ‐‐‐  ‐‐‐  neg 
CRESCENTIC GLOMERULONEPHRITIS 
RTI = Respiratory  Tract Infection;     + =present;   ‐ =absent  HT = Hypertension;  DM = Diabetes mellitus; CVA = Cerebro Vascular Accident  
Sl. 
no 
Name   Age/
sex 
                    Presenting symptoms       Prodromal/Preceding events        Antecedent problems   
edema   oliguria  anuria  hematur
ia 
Duration   RTI  fever  Drug/toxin/others    HT  DM others 
1  Vignesh   15M  +  ‐  ‐  +  15 days  ‐  ‐  ‐  ‐  ‐  ‐ 
2  Narayanan   47M  +  +  +  +  30 days  ‐  ‐  Smoking  (40py)  ‐  ‐  ‐ 
3  Suresh   18M  +  ‐  ‐  ‐  7 days  ‐  ‐  Scabies  +  ‐  HSP 
4  Mumtaj   26F  +  +  ‐  ‐  30 days  ‐  ‐  ‐  ‐  ‐  ‐ 
5  Sambasivam   60M  +  +  ‐  +  14 days  ‐  ‐  Insect bite,drugs(?)  ‐  ‐  ‐ 
6  Munusamy   70M  +  ‐  ‐  ‐  11  days  ‐  +  Envas, Sumo  +  ‐  CVA 
7  Rajammal   40F  +  +  ‐  +  5 days  ‐  +  GTCS – 7 episodes  ‐  ‐  ‐ 
8  Periyandavar   35M  +  ‐  ‐  +  14 days  ‐  ‐  ‐  ‐  ‐  DCLD/PHT/varices 
9  Elumalai   63F  +  +  +  ‐  35 days  +  +  Smoking  (25 py)  ‐  ‐  ‐ 
10  Ramanibai   52F  +  +  +  ‐  3 days  ‐  ‐  Amlodipine  +  ‐  Rash  
11  Dharman   33M  +  ‐  ‐  ‐  20 days  ‐  ‐  ‐  ‐  ‐  Edema – 1 year 
12  Karthik   15M  +  +  +  ‐  7 days  ‐  +  ‐  ‐  ‐  ‐ 
13  Shanthi   26F  +  +  ‐  ‐  20 days  ‐  ‐  ‐  +  ‐  K/C/O Class 4 LN, 
refused therapy
14  Balakrishnan   18M  +  ‐  ‐  ‐  8 days  ‐  +  Antipyretic (?drug)  ‐  ‐  ‐ 
15  Jayamani   68F  +  ‐  ‐  ‐  14 days  ‐  +  Filarial lymphangitis/DEC ‐  ‐  K/C/O filarial leg 
16  Feroz khan   16M  +  +  +  ‐  3 days  ‐  ‐  ‐ +  ‐  K/C/O Class 4 LN, on 
NIH, 3 pulses over
17  Valliammal   65F  +  +  +  ‐  6 days  ‐  +  Diarrhea, drugs(?)  ‐  ‐  ‐ 
18  Nirmala   27F  +  +  ‐  ‐  7 days  ‐  ‐  2nd pregnancy, 8MA  ‐  ‐  No PIH in 1st pregn. 
19  Ezhilarasi   30F  +  +  ‐  +  10 days  ‐  +  Fever – 20 days   ‐  ‐  2 spontaneous abortions 
20  Shaheen   17F  +  +  ‐  ‐  10days  ‐  +    +  ‐  K/C/O Class 4 LN,NIH 
completed , partial rem 
21  Nooriya zarith  23F  +  ‐  ‐  ‐  25 days  ‐  ‐  1st pregnancy, 8MA  ‐  ‐  ‐ 
22  Umesh   25M  +  +  ‐  ‐  24 days  ‐  ‐  ‐  ‐  ‐  ‐ 
23  Jayanthi   17F  +  +  +  ‐  5 days  ‐  +  Diarrhea  +  ‐  K/C/O Class 4 LN, on 
NIH , partial remission 
24  Kavitha   14F  +  +  +  +  15 days  +  +  ‐  ‐  ‐  ‐ 
25  Soundarya   15F  +  ‐  ‐  ‐  12 days  ‐  ‐  ‐  +  ‐   
26  Kalaimathy   22F  +  +  ‐  ‐  8 days  ‐  ‐  Diarrhea   +  ‐  K/C/O Class 4 LN,NIH 
completed , partial rem 
CRESCENTIC GLOMERULONEPHRITIS 
 
‐  = absent;  + = present; (d) =  with anti hypertensive drugs; LL = Lower limbs; LUL = Left upper limb 
Sl. 
no 
Name                        Extra renal  symptoms                                             Clinical examination 
rash   arthralgia hemoptysis Others   BP                            General & systemic examination 
1  Vignesh   ‐  +  ‐  Oral ulcers,seizures  200/110  Gen. lymphadenopathy, oral ulcers, minor jt. arthritis 
2  Narayanan   +  ‐  ‐  ‐  140/90  Fixed drug eruption, cheilitis, Rt residual Bells palsy 
3  Suresh   ‐  +  ‐  ‐  110/70 (d)  Scabies  
4  Mumtaj   ‐  ‐  ‐  Excess hair loss  140/80  Nil specific 
5  Sambasivam   ‐  ‐  ‐  ‐  156/90  Nil specific 
6  Munusamy   ‐  ‐  ‐  Myalgia   160/100  Right hemiparesis(residual) power 4/5 
7  Rajammal   ‐  ‐  ‐  weakness LL &LUL  160/100  Pyramidal weakness of both LL & LUL  
8  Periyandavar   ‐  ‐  ‐  ‐  120/80  Ascites, hepatosplenomegaly, distended veins 
9  Elumalai   ‐  ‐  ‐  wheezing  210/120  Nil specific 
10  Ramanibai   +  ‐  ‐  ‐  150/90 (d)  Palpable purpura  over lower limbs, evanescent 
11  Dharman   ‐  ‐  ‐  ‐  170/110  Nil specific  
12  Karthik   ‐  ‐  +(1 month)  Cough – 1 month  170/120  RS: B/L coarse crepitations 
13  Shanthi   ‐  +  ‐  ‐  120/80 (d)  Nil specific 
14  Balakrishnan   ‐  ‐  ‐  ‐  200/100  Nil specific 
15  Jayamani   ‐  +  ‐  ‐  156/90  Lymphedema left lower limb 
16  Feroz khan   +  +  ‐  ‐  130/80 (d)  Hyperpigmented macules over trunk & limbs 
17  Valliammal   ‐  ‐  ‐  ‐  140/90  Nil specific 
18  Nirmala   ‐  ‐  ‐  ‐  160/96  Uterus 32 weeks, FH heard 
19  Ezhilarasi   ‐  ‐  ‐  ‐  150/90  Nil specific 
20  Shaheen   +  ‐  ‐  pleurisy  180/100  Erythema nodosum, pleuritis, pericardial effusion 
21  Nooriya zarith  ‐  ‐  ‐  Antepartum 
haemorrhage at 8MA
140/100  Uterus involuted 
22  Umesh   ‐  ‐  ‐  ‐  166/100  Nil specific 
23  Jayanthi   ‐  +  ‐  ‐  170/100  Nil specific 
24  Kavitha   ‐  ‐  ‐  ‐  156/90  Nil specific 
25  Soundarya   ‐  +  ‐  Seizures   170/100  Nil specific  
26  Kalaimathy   ‐  +  ‐  Seizures  186/100  Nil specific 
Sl.no  Name   Final diagnosis 
(Etiology) 
Time to 
specific Rx 
from  onset 
of symptoms
whether 
dialysis 
required 
           Treatment given                        Outcome  
  Steroid  Cyclo.  Plasmapheresis
MMF/others 
 Creatinine 
(μmol/l) 
Urine PCR 
3 mon  6mon  3mon  6mon 
1  Vignesh   Lupus nephritis  24 days  No   IV /PO  IV  none  65  74  2.3  2.2 
2  Narayanan   Vasculitis – renal limited  38 days  Yes   IV/PO  PO  none  273  *  1.6  * 
3  Suresh  Henoch Schonlein nephritis  13 days  No  PO  PO  none  128  169  3.8  4.6 
4  Mumtaj   Lupus nephritis  7 days  yes  IV/PO  IV  none  178  Exp.  2.1  Exp. 
5  Sambasivam   PIGN  20 days  yes  IV/PO  ‐  none  *  *  *  * 
6  Munusamy    Vasculitis –renal limited  ‐‐  yes  ‐  ‐  none  336  293  1.2  1.1 
7  Rajammal   PIGN  9 days  yes  IV/PO  ‐  none  495  170  4.6  1.5 
8  Periyandavavar   Vasculitis/DCLD   ‐‐  yes  ‐  ‐  ‐  286  174  1.8  1.1 
9  Elumalai   PIGN  27 days  yes  IV/PO  ‐  ‐  Dial.  Dial.   Dial.   Dial.  
10  Ramanibai   Henoch Schonlein nephritis  10 days  yes  IV/PO  ‐  none  242  *  2.4  * 
11  Dharman   Membranous nephropathy  ‐‐  yes  ‐  ‐  ‐  Dial.  *  Dial.  * 
12  Karthik   Anti GBM disease  35 days  yes  IV/PO  PO  Plasmapheresis  Exp.  Exp.  Exp.  Exp. 
13  Shanthi   Lupus nephritis   15 days  yes  IV/PO  IV  ‐  *  *  *  * 
14  Balakrishnan   Vasculitis – renal limited  15 days   Yes  IV/PO  PO  ‐  *  *  *  * 
15  Jayamani   Vasculitis – renal limited  7 days   No   PO  PO  ‐  186  *  1.3  * 
16  Feroz khan   Lupus nephritis  5 days   yes  IV/PO  IV  ‐  Dial.  Dial.  Dial.  Dial. 
17  Valliammal   Vasculitis – renal limited  10 days  yes  IV/PO  PO  Plasmapheresis  *  *  *  * 
18  Nirmala   PIGN  9 days  yes  IV/PO  ‐  Pregnancy 
terminated
*  *  *  * 
19  Ezhilarasi   Lupus nephritis  16 days   Yes   IV/PO  IV  ‐  112  90  1.2  2.8 
20  Shaheen   Lupus nephritis  10 days   Yes   IV/PO  ‐  MMF  148  *  1.4  * 
21  Nooriya zarith  IgA  nephropathy  ‐‐  Yes   ‐  ‐  Pregnancy 
terminated
Exp.  Exp.  Exp.  Exp. 
22  Umesh   IgA nephropathy  30 days  yes  IV/PO  PO  ‐  Dial.  Dial.  Dial.  Dial. 
23  Jayanthi   Lupus nephritis  10 days  yes  IV/PO  IV  ‐  Dial.  Dial.  Dial.  Dial. 
24  Kavitha   Anti GBM disease  ‐‐  yes  ‐‐  ‐  ‐  Dial.  *  Dial.  * 
25  Soundarya   Lupus nephritis   39 days  Yes   IV/PO  IV  ‐  114  *  1.8  * 
26  Kalaimathy   Lupus nephritis   ‐‐  Yes   ‐  ‐  ‐  Dial.  Exp.  Dial.  Exp. 
* = no followup; Exp. = Expired; PIGN= Post Infectious Glomerulo Nephritis; ‐ = not given;  ‐‐ = not applicable; Dial. = Dialysis dependent 
                                     OUTCOME AT ONE MONTH FOR THOSE PATIENTS WHO WERE THEN  LOST  FOR FOLLOWUP  
                                            
 
 
 
 
                                  
                     
 
 
 
 
SL.NO  NAME   RENAL FUNCTION/ CREATININE  EXTRA RENAL MORBIDITY  
5  Sambasivam   Dialysis dependent  None 
13  Shanthi   Dialysis dependent  None  
14  Balakrishnan    creatinine = 428 μmol/l,  dialysis 
independent   
None  
17  Valliammal   Dialysis dependent  None  
18  Nirmala   Creatinine = 93  μmol/l,  dialysis 
independent   
None 
 
DETAILS OF PATIENTS WHO WERE MANAGED WITHOUT IMMUNOSUPPRESSION  
DCLD = Decompensated liver disease; * = No follow up 
 
Sl.no  Name   Diagnosis   Reason for avoiding 
immunosuppression 
                                  Outcome  
Creatinine(µmol/l)  Urine PCR 
3 months  6 months  3months  6 months 
6  Munusamy   Vasculitis –renal 
limited 
Pyelonephritis   336  293  1.8  1.3 
8  Periyandavar   Vasculitis /DCLD   DCLD, portal hypertension & 
esophageal varices 
286  174  1.8  1.1 
11  Dharman   Membranous 
nephropathy 
Late presentation   Dialysis 
dependent 
*  Dialysis 
dependent 
* 
21  Nooriya zarith   IgA nephropathy   Late presentation ,  chronic 
tubulo interstitial changes in 
biopsy, deranged LFT 
expired  expired  expired  expired 
24  Kavitha   Anti GBM nephritis  Late presentation  Dialysis 
dependent 
*  Dialysis 
dependent 
* 
26  Kalaimathy   Lupus nephritis  Late presentation , chronic 
tubulointerstitial changes & 
fibrous crescents in biopsy 
Dialysis 
dependent 
expired  Dialysis 
dependent 
expired 
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A study of Crescentic Glomerulonephritis – Etiology, clinical presentation, outcome & 
prognostic factors: 
 
Name: Age/sex: NC.No: DOA: 
  
Presenting Symptoms: 
 
Edema   
Oliguria   
Haematuria   
Extrarenal symptoms  
Duration of symptoms   
  
Past medical history: 
Diabetes mellitus   
HT   
Jaundice  
Edema, haematuria   
 
Smoking   
Alcohol use   
Obstetric history   
 
 
Examination:  
 
Edema   Pulse   
Pallor  BP  
Icterus   RR  
Lymphnodes   Temp   
Skin  CVS  
ENT   RS  
Eyes  Abdomen  
Fundus  CNS   
Bone & joints    
 
 
 
 
 
Diagnosis:  
 
 
 
 
 
 2
Investigations: 
Urine: 
 
 
Blood:  
Hb  Serologic workup for RPGN: 
Platelet count   
BT,CT   
Peripheral smear   
PT & INR   
Serum Na+ / K+   
Serum cholesterol   
Serum Bilirubin   
SGOT/SGPT   
 
Renal function: 
        
        
 
Others: 
CXR /CT Thorax:  
USG Abdomen:  
Xray PNS/ CT PNS:  
Others:  
 
Renal Biopsy: 
  
Treatment : 
 
 
 
Outcome:  
1 month 3 months  6 months   
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Figure 1:  X axis represents the number of patients; events preceding the occurrence of RPGN are marked along the Y axis. 
Fever with or without diarrhea/respiratory infection appears to be the most common prodromal manifestation  
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Figure 2: X axis represents the number of patients; major symptoms at clinical presentation are plotted along the Y axis 
 
 
 Figure  3:  Oliguric,  anuric  and  nonoliguric  presentations  of  Crescentic  Glomerulonephritis.  Numbers  within  each  sector 
represents the number of patients (% of total population) in each category 
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Figure 4: X axis represents the number of patients and the various extra renal manifestations are plotted along the Y axis 
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Figure  5:  X  axis  represents  diastolic  BP  in mm  Hg;  Y  axis  represents  systolic  BP  in mm  Hg.  The  BP  trend  of  the  study 
population, excluding four patients who were already on antihypertensive drugs at the time of admission is represented as 
scatter diagram 
 
 
 
 
 
 
 
0
50
100
150
200
250
0 20 40 60 80 100 120 140
Blood Pressure at presentation in Crescentic 
Glomerulonephritis 
  
Figure 6: The three pathological categories of Crescentic glomerulonephritis based on immunofluorescence are represented 
along the X axis; Y axis represents the number of patients. 
  
Figure 7: Etiology of  Immune Complex Glomerulonephritis based on immunofluorescence & serologic tests. Y axis represents 
the  number  of  patients.  IgAN  =  IgA  Nephropathy;  HSP  =  Henoch  Schonlein  nephritis:  PIGN  =  Post  Infectious 
Glomerulonephritis; Memb. Neph. = Membranous Nephropathy  
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Figure 8: The  three  types of Crescentic Glomerulonephritis are plotted along  the X axis. Y axis  represents  the number of 
patients. 
  
Figure 9: The average spot urine protein creatinine ratio at the time of clinical presentation is represented along Y axis.  
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 Figure 10: Out of the seven patients with lupus nephritis who were tested for ANA five were found to be ANA positive and 
two were ANA negative. 
 
Figure 11: Out of the six patients who had vasculitis, ANCA was positive in two and negative in the remainder. In both only  
P‐ANCA was positive. 
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Figure 14: The various  specific  therapeutic  strategies adapted are plotted along  the Y axis and  the Y axis  represents  the 
number of patients treated with a particular strategy. 
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